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In this paper we describe an alteration of the c-myc oncogene present in the white blood cells and normal 
as well as neoplastic thyroid cells of a subject carrying a thyroid carcinoma. Restriction enzyme mapping 
and hybridization to human c-myc probes specific for different regions of this gene demonstrate that this 
subject carries, in addition to the normal one, a c-myc oncogene lacking the first exon and part of the first 
intron. The levels of the c-myc mRNA in thyroid cells of this subject do not show differences with respect 
to thyroid cells from other subjects. Taken together, these findings indicate that the deletion of the first 
exon of the c-mvc oncogene. in itself, does not produce overtranscription of this oncogene nor hematopoietic 
malignancies. 
c-myc oncogene DNA alteration 
1. INTRODUCTION 
Much evidence indicates that cellular oncogenes 
are implicated in the genesis of cancer [ 1,2]. 
Alterations of the structure and expression of these 
genes are indeed frequently observed in neoplastic, 
but not in normal cells [l-3]. 
The c-myc oncogene, for instance, was found 
amplified, translocated and rearranged in tumors 
of different origins, such as leukemias, lymphomas 
and carcinomas 14-61. In normal cells this gene is 
organized in 3 exons, the first of which represents 
a non-coding leader sequence and contains two 
promoter sites [5,7]. In some Burkitt lymphomas 
and leukemias a complete or a decapitated c-myc 
oncogene (lacking both the first exon and part of 
the first intron) is translocated to transcriptionally 
active regions of the human genome such as those 
containing the immunoglobulin heavy chain locus 
(5,7]. The rearranged c-myc oncogenes are overex- 
pressed, while the normal gene is silent or ex- 
pressed at very low levels [5]. Recent experiments 
RNA level NeopIastic transformation 
reported by a number of laboratories suggest hat 
there are probably multiple steps in the transcrip- 
tional activation of this oncogene including its 
translocation near enhancer elements [S], point 
mutations or the deletion of regulatory sequences 
involved in the repression of its expression [8,9], 
Here, we describe a partial deletion of the c-myc 
oncogene identified in a subject carrying a thyroid 
carcinoma. The alteration of the c-myc oncogene 
was found to be present in the peripheral white 
blood cells, and neoplastic thyroid cells as well as 
the corresponding normal thyroid cells, being 
therefore presumably fixed in the genome of this 
subject. 
2. MATERIALS AND METHODS 
2.1. DIVA preparalion 
DNA was isolated from peripheral blood cells 
and thyroid tissues by proteinase K treatment and 
phenol-chloroform extraction as described [ 10). 
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2.2. Southern blotting 
Approx. 1Opg of each DNA sample were 
digested with one or two restriction enzymes 
following experimental conditions specified by the 
supplier (Boehringer-Mannheim). Restriction en- 
zyme generated fragments were electrophoresed on 
0.8% agarose gels and transferred to nitrocellulose 
filters (Gene Screen-NEN) [lo]. 
2.3. Cytoplasmic dot hybridization 
Cytoplasmic preparations were obtained from 
white blood cells or tissue slices and treated with 
formaldehyde as in [lo]. 
2.4. Filter hybridization 
The filters were prehybridized and hybridized in 
the presence of 50% formamide and dextran 
sulfate as reported [lo] with nick-translated t3’P]- 
DNA probes (spec. act. lo8 cpm/pg) [lo]. After 
40 h of hybridization for DNA and 24 h for RNA, 
the filters were washed [lo] and exposed to Kodak 
X Omat AR5 with intensifying screens (DuPont). 
3. RESULTS 
DNAs from the white blood cells of patients car- 
rying different solid tumors were digested with 
EcoRI restriction enzyme, which recognizes DNA 
sequences outside of the c-myc oncogene, as in- 
dicated in the map shown in fig.1. 
Fig.2 shows the autoradiographic patterns ob- 
tained after hybridization of the 3 ’ c-myc DNA 
probe to the EcoRI-restricted DNAs isolated from 
13 different subjects. The 12.5 kb band expected 
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Fig.1. c-myc gene probes employed: pMC41SPP, 5’ 
probe 131; pMC413RC, 3’ probe [3]; the exon 1 probe is 
an XhOI-fiuII fragment [14] and the intron 1 probe an 
~acr-&?cI fragment (kind gift from Dr F. Mavilio, Lab. 
Ematologia, 1st. Superiore di Sanita, Rome). The 
restriction enzyme map of the human c-myc oncogene 
was derived from [3]. X, XbaI; E, EcoRI; H, HhdIII. 
Boxes represent exons l-3 of the oncogene. 
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Fig.2. Left: autoradiographic pattern of the c-myc 
specific fragments obtained after EcoRI digestion of 
DNA from subjects carrying different solid tumors, in- 
cluding lung, thyroid and colon carcinomas. Nitro- 
cellulose filters were hybridized to the 3’ c-myc probe. 
The faint band in case 3 is due to incomplete digestion. 
Right: Southern blot of the DNA from normal (N) and 
carcinomatous (C) thyroid samples of case 6 are also 
shown. 
as for normal DNA is present in all the samples. In 
case 6, an additional band, 8.5 kb in size, is pre- 
sent (fig.2, left). A similar double band pattern is 
also present in the normal (N) as well as neoplastic 
(C)thyroid tissues of this subject (fig.2, right). The 
abnormal c-myc EcoRI pattern could be compati- 
ble with (i) a DNA deletion of about 4 kb or (ii) an 
EcoRI polymorphism which introduces a new 
EcoRI site in one of the two c-myc genes of this 
subject. 
To distinguish between these two possibilities 
the DNA of case 6 was digested with XbaI and 
Hind111 restriction enzymes, used alone or in com- 
bination with EcoRI. 
In addition to the normal fragment as expected 
from the map in fig. 1, an abnormal band is ob- 
tained after XbaI, EcoRI and Hind111 digestion 
and hybridization to the 3’ c-myc probe (fig.3.). 
After EcoRI and Hind111 digestion, the additional 
DNA fragment is smaller in size, whereas it is big- 
ger after XbaI digestion. 
These results clearly indicate that the abnormal 
c-myc EcoRI pattern is not caused by an EcoRI 
polymorphism, but might be due to a deletion of 
at least 4 kb which starts after the first Hind111 site 
(see the map in fig.1) and eliminates the XbaI site 
located in the first intron. 
To analyse more accurately this putative 4 kb 
deletion within the c-myc gene, we have hybridized 
the EcoRI-generated fragments of case 6 with 
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Fig.3. c-myc specific fragments of carcinomatous 
thyroid DNA from case 6 after digestion with XbaI (X), 
XM-EcoRI (X-E), EcoRI (E), EcoRI-Hind111 (E-H) 
and Hind111 (H). Fragments not expected for normal 
DNA are indicated by arrowheads. The asterisk in- 
dicates the presence of a double band barely visible in 
the photograph. This double band contains the abnor- 
mal fragment slightly separated from the normal ex- 
pected one. On the left and right are shown Hind111 
(left) and EcoRI (right) digested h phage DNA. 
DNA probes specific for different regions of the 
gene such as the 5 ’ half (5 ‘), exon 1 (Exl) and 
intron 1 (Ivsl) (see fig.l.). The results are 
presented in fig.4A. 
The additional EcoRI band of 8.5 kb hybridizes 
with the 5 ’ probe, which includes exon 1, intron 1 
and part of exon 2, and with the Ivsl probe, but 
does not do so with the Exl probe. Accordingly, 
only normal c-myc DNA fragments were obtained 
after re-hybridization of the Southern blot shown 
in fig.3 with the Exl c-myc probe (not shown). 
Taken together the results obtained after 
hybridization with the Exl probe and by using 3 
restriction enzymes (X6a1, Hind111 and EcoRI) 
strongly indicate that the deletion includes the first 
exon leaving intact the second and third exon (see 
map in fig.4B). 
The possible overexpression of this truncated 
oncogene was investigated in both the normal as 
well as carcinomatous thyroid samples of this sub- 
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Fig.4. (A) c-myc specific fragments in the white blood 
cell DNA from a normal subject (control) and case 6. 
The DNA was digested with EcoRI restriction enzyme, 
and the nitrocellulose filters hybridized with c-myc 
probes specific for the 5 ‘half, exon 1 (Exl) and intron 1 
(Ivsl) of the gene. (B) Proposed restriction enzyme map 
of the DNA of subject 6, containing the normal as well 
as truncated c-myc oncogene as deduced by data from 
fig.3 and this figure. 
ject by using cytoplasmic dot blot hybridization as 
described elsewhere [lo]. 
The results obtained in the normal thyroid 
samples from a control individual and subject 6 
are shown in fig.5. 
The levels of c-myc mRNA, hybridized to the 3 ’ 
c-myc probe were normalized with respect o their 
ribosomal RNA content, evaluated after 
hybridization with the plasmid pXCR7, carrying 
sequences pecific for 28 S and 18 S rRNAs. 
These data indicate that in the cells of case 6, 
carrying the abnormal oncogene in addition to the 
normal one, no significant increase in overall c- 
myc mRNA levels is appreciable. Similar results 
were obtained studying c-myc RNA expression in 
the carcinomatous thyroid of subject 6 (not 
shown). By contrast, much higher levels of c-myc 
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Fig.5. Cytoplasmic dot blot hybridization of normal thyroid samples from a subject carrying a goiter (control) and 
subject 6, carrying a papillary carcinoma. The autoradiographic spots after filter hybridization with 3’ c-myc probe 
and pXCR7 ribosomal probe are shown (left) as well as the plots of their densitometric analysis (right). 
mRNA were detected in other tumor cells such as 
HL-60 or cells isolated from a colon carcinoma 
and a kidney carcinoma (not shown). 
4. DISCUSSION 
Alterations in the structure of the c-myc on- 
cogene such as duplications, translocations, or 
point mutations have been reported by several 
authors in different tumors such as leukemias, 
lymphomas and carcinomas, but not in normal 
cells [2-51. 
After the analysis of EcoRI c-myc specific 
fragments from the white blood cells of 50 subjects 
carrying solid tumors, we found only one subject 
showing alteration of the c-myc oncogene. This 
alteration was present in both the blood cells and 
the thyroid side of the tumor. This subject might 
therefore be considered heterozygous for a rare 
variant of the c-myc gene. 
The alteration observed was further character- 
ized and turned out to be a deletion involving the 
first exon, which does not codify for the c-myc 
protein [5-71 but does contain promoter sites, be- 
ing therefore important for the correct transcrip- 
tion of the c-myc gene [5,7,8]. 
Since after hybridization with the exon 1 probe 
no EcoRI fragment was observed in addition to the 
12.5 kb band (fig.4), we exclude, in this case, the 
presence of a translocation. In addition, the 
analysis of the chromosome map of this subject 
does not reveal any rearrangement and in situ 
hybridizations with the 3 ’ c-myc probe show ap- 
preciable radioactivity only on the long arm of 
chromosome 8 (not shown). 
The isolation and characterization of c-myc 
specific clones from a genomic library of this sub- 
ject would be useful to define the extent of the 
deletion of DNA sequences upstream of the first 
exon of the c-myc oncogene. 
Expression of the c-myc oncogene in the thyroid 
cells of the case presenting the c-myc gene altera- 
tion is at the same level of other normal thyroid 
samples examined. 
These results suggest hat exon 1 is nor primarily 
involved in the negative regulatory functions dur- 
ing the transcription of the c-myc gene, as con- 
trastingly proposed by Leder et al. [S] and Kelly et 
al. [ll]. 
In addition, it is remarkable that no tumor cells 
are present in the peripheral blood cells of this pa- 
tient . 
Our data therefore are of interest when related 
to the studies proposed by Saito et al. [12] and 
Darveau et al. [13] which indicate that in both 
mouse and man the translation of full-length c- 
myc mRNA is much less efficient compared to that 
of the c-myc mRNAs carrying deletions of the 
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5 ‘-non-coding region. Similar post-translational [3] DAlla Favera, R., Martinotti, S., Gallo, R.C., 
control was hypothesized to cause several Burkitt Erikson, J. and Croce, C.M. (1983) Science 219, 
lymphomas [ 121. 963-967. 
Taken together, the present data demonstrate 
that (i) the presence of a truncated c-myc oncogene 
lacking exon 1 might be uncoupled with 
hematopoietic malignancies and (ii) the deletion of 
the first exon, in itself, does not cause over- 
transcription of this oncogene. 
[4] Collins, S. and Groudine, M. (1982) Nature 298, 
679-68 1. 
[S] Croce, C.M. and Nowell, C.P. (1984) New Trends 
in Experimental Hematology (Serono Symposia) 7, 
240-253. 
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